Liraglutide (recombinant) is a non-glycosylated analogue of GLP-1 (glucagon-like peptide). It enhances glucose-dependent insulin secretion following its release into the circulation from the gut. It is a 31 amino acid peptide molecule with molecular weight of 3384 Da. The attachment of Hexadecanoic acid to the amino acid to the amino group of Lysine 26 of the GLP-1 analogue via a glutamic acid spacer results in the formation of Liraglutide.

Status:
  • Pre-clinical studies completed in India as per schedule Y of Drugs & Cosmetics Act, India
Indications:
  • As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.